Addus HomeCare (ADUS) Q2 Revenue Up 22%

Addus HomeCare (ADUS) reported robust Q2 2025 financial results, with revenue increasing 21.8% year-over-year to $349.4 million and non-GAAP EPS rising 10.4% to $1.49, both exceeding analyst consensus. This strong performance was primarily driven by significant organic growth in its Personal Care (7.4%) and Hospice (10.0%) segments, complemented by recent acquisitions. While the Home Health segment saw a slight year-over-year decline, the company maintains a strategic focus on operational efficiency, technology integration, and accretive acquisitions, underpinned by solid cash flow and a conservative balance sheet, while closely monitoring government reimbursement rates.

Analysis

Addus HomeCare (ADUS) delivered a strong second quarter for 2025, exceeding analyst estimates on both revenue and earnings. Total revenue grew 21.8% year-over-year to $349.4 million, beating consensus by $2.9 million, while non-GAAP EPS rose 10.4% to $1.49, surpassing expectations by $0.02. This performance was driven by a combination of acquisitive growth, notably from the Gentiva integration, and robust organic growth in its two largest segments. The Personal Care division, representing 77% of revenue, posted 7.4% organic growth, significantly above its 3-5% long-term target, fueled by state-mandated rate increases in markets like Illinois and higher service hours per client, which successfully compensated for a slight decline in the total billable census. The Hospice segment also demonstrated significant strength with 10.0% organic growth, supported by a 7.0% increase in its average daily census. In contrast, the much smaller Home Health segment continued to underperform, with organic revenue declining 6.0% and new admissions dropping 7.6%, reinforcing management's view of it as a complementary service rather than a primary growth engine. The company's strategic focus on technology, such as its proprietary scheduling app, and its disciplined M&A strategy are supported by healthy cash flow from operations ($22.5 million) and a conservative balance sheet. The key forward-looking risk remains the company's high dependence on government payors, making reimbursement rate stability a critical factor for future profitability.

Key Decisions for Investors

• The strong earnings beat and robust organic growth in the core Personal Care and Hospice segments provide a solid bullish thesis, suggesting the current strategy is executing effectively.
• Investors should closely monitor the sustainability of Personal Care's growth, particularly the interplay between a declining client census and rising revenue per client, to gauge future performance.
• The primary risk factor is regulatory dependency; therefore, any shifts in Medicaid or Medicare reimbursement policies in key states represent a material threat to revenue and margins and must be watched closely.
• Given the underperformance of the Home Health segment, investors should assess whether management's strategy of targeted acquisitions can stabilize this division or if it will remain a drag on overall organic growth.